中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

94 records (took 0.035 seconds)

    MULTI-LAYER SKIN SUBSTITUTE PRODUCTS AND METHODS OF MAKING AND USING THE SAME
    54.
    发明申请
    MULTI-LAYER SKIN SUBSTITUTE PRODUCTS AND METHODS OF MAKING AND USING THE SAME 审中-公开

    公开(公告)号：US20170354763A1

    公开(公告)日：2017-12-14

    申请号：US15542095

    申请日：2016-01-11

    Applicant: Wake Forest University Health Sciences

    Inventor： Anthony Atala ,  Gayoung Jeong ,  James J. Yoo ,  Sang Jin Lee ,  Young-Joon Seol

    IPC: A61L27/60 ,  B33Y80/00 ,  G01N33/50 ,  B33Y70/00 ,  B29C64/106 ,  A61F2/10 ,  B33Y10/00 ,  A61L27/18 ,  A61L27/38 ,  A61L27/52 ,  B29K75/00 ,  B29K105/00

    Abstract: Provided are live, artificial, skin substitute products and methods of making and using the same, such as for wound treatment and compound testing, including compound testing for efficacy, toxicity, penetration, irritation and/or metabolism testing of drug candidates or compositions such as cosmetics. Described herein is an artificial mammalian skin substitute product, comprising: (a) optionally, but in some embodiments preferably, a first (“hypodermis-like”) layer comprising live mammalian adipocytes (e.g., induced pre-adipocytes) in a first hydrogel carrier; (b) a second (“dermis-like”) layer contacting or directly contacting the first layer and comprising live mammalian fibroblast cells and' live mammalian follicle dermal papilla cells in combination in a second hydrogel carrier; (c) a third (“epidermis-like”) layer contacting or directly contacting the second layer (i.e., on the opposite side thereof as the first layer, so that the second layer is sandwiched between the first and third layers when the first layer is present), the third layer comprising live mammalian keratinocytes and live mammalian melanocytes in combination in a third hydrogel carrier.

    ENCAPSULATED CELLS FOR HORMONE REPLACEMENT THERAPY
    57.
    发明申请
    ENCAPSULATED CELLS FOR HORMONE REPLACEMENT THERAPY 审中-公开
    用于激素替代治疗的包封细胞

    公开(公告)号：US20160166620A1

    公开(公告)日：2016-06-16

    申请号：US14909240

    申请日：2014-09-02

    Applicant: WAKE FOREST UNIVERSITY HEALTH SCIENCES

    Inventor： Emmanuel C. Opara ,  James J. Yoo ,  Justin M. Saul ,  Sittadjody Sivanandane ,  Anthony Atala

    IPC: A61K35/54 ,  A61K31/565 ,  A61K9/50 ,  A61K35/28

    CPC classification number: A61K35/54 ,  A61K9/5036 ,  A61K9/5052 ,  A61K9/5073 ,  A61K31/565 ,  A61K31/57 ,  A61K35/28 ,  A61K47/36

    Abstract: A composition comprising microcapsules, the microcapsules containing both live mammalian ovarian granulosa cells and live mammalian ovarian theca cells, is described. In some embodiments, the granulosa cells and the theca cells are contained in separate microcapsules in the composition; in some embodiments, the granulosa cells and the theca cells are contained together in the same microcapsules in the composition. The composition is can be used for estrogen, and optionally also progesterone, delivery, and hence is preferably free or essentially free of oocytes. Methods of using the same and pharmaceutical formulations containing the same are also described.

    Abstract translation: 描述了包含微胶囊的组合物，包含活哺乳动物卵巢颗粒细胞和活哺乳动物卵巢细胞的微胶囊。 在一些实施方案中，颗粒细胞和细胞被包含在组合物中的分离的微胶囊中; 在一些实施方案中，颗粒细胞和细胞在组合物中一起包含在相同的微胶囊中。 该组合物可用于雌激素，并且任选地也可用于孕酮，递送，因此优选为游离或基本上不含卵母细胞。 还描述了使用它们的方法和含有它们的药物制剂。

    SELECTIVE CELL THERAPY FOR THE TREATMENT OF RENAL FAILURE
    59.
    发明申请
    SELECTIVE CELL THERAPY FOR THE TREATMENT OF RENAL FAILURE 审中-公开
    用于治疗失败的选择性细胞治疗

    公开(公告)号：US20160002603A1

    公开(公告)日：2016-01-07

    申请号：US14856043

    申请日：2015-09-16

    Applicant: Wake Forest University Health Sciences

    Inventor： Anthony Atala ,  James J. Yoo

    IPC: C12N5/071 ,  G01N15/10 ,  G01N33/569 ,  A61K35/22 ,  A61K9/00

    CPC classification number: C12N5/0686 ,  A61K9/0024 ,  A61K35/12 ,  A61K35/22 ,  C12N2500/02 ,  C12N2502/256 ,  G01N15/1031 ,  G01N33/56966 ,  G01N2015/0065 ,  G01N2015/1081

    Abstract: Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein cells have been expanded in vitro. The kidney cells may include peritubular interstitial cells of the kidney, and preferably produce erythropoietin (EPO). The kidney cells may also be selected based upon EPO production. Methods of producing an isolated population of EPO producing cells are also provided, and methods of treating a kidney disease resulting in decreased EPO production in a patient in need thereof are provided, including administering the population to the patient, whereby the cells produce EPO in vivo.

    Abstract translation: 本文提供从肾分化细胞收获的分离的肾细胞群体，其中细胞已经在体外扩增。 肾细胞可以包括肾的肾周间质细胞，并且优选产生促红细胞生成素（EPO）。 也可以基于EPO生产来选择肾细胞。 还提供了产生分离的EPO产生细胞群体的方法，并且提供了在有需要的患者中治疗导致EPO产生减少的肾脏疾病的方法，包括向患者施用群体，由此细胞在体内产生EPO 。

Patent Agency Ranking